Posts by: Steve Bryson PhD

Steve Bryson PhD

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

December 3, 2020December 3, 2020

CRISPR-Cas9 in Lipid Nanoparticles Found to Safely Treat Ovarian Cancer in Mice

News

For the first time, researchers safely and effectively treated cells and mice with ovarian cancer using the CRISPR-Cas9 gene-editing tool plus a newly developed lipid nanoparticle (LNP) delivery system, which ... Read more

October 6, 2020October 6, 2020

Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show

News

When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of ... Read more

July 16, 2020July 16, 2020

Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial

News

The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent ... Read more

March 23, 2020March 23, 2020

Cellular Recycling Genes Linked to Ovarian Tumor Formation in Mice, Study Shows

News

Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors, a study in ... Read more

March 6, 2020March 23, 2020

Women With Low LDL Have Lower Ovarian Cancer Risk, Genetic Analysis Shows

News

Women with naturally lower levels of LDL cholesterol have less risk of ovarian cancer, regardless of mutations in BRCA genes, a genetic analysis study revealed. The findings suggest a role ... Read more

February 14, 2020February 14, 2020

Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows

News

A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian cancer ... Read more

January 20, 2020January 20, 2020

Add-on NAMPT Inhibitor Prolonged Survival in Ovarian Cancer Mouse Model, Study Found

News

Using standard platinum-based chemotherapy is often associated with the formation of unfavorable treatment-resistant cancer stem cells, which may ultimately contribute to cancer progression — but inhibiting an enzyme called NAMPT ... Read more

January 8, 2020

Second Surgery for Recurrent Ovarian Cancer Does Not Improve Survival, Phase 3 Trial Shows

News

A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian cancer who experienced disease recurrence after a first surgery. ... Read more

October 21, 2019

Ovarian Cancer Research Led By David Alberts Given Boost By $5M Memorial Gift

News

The search for a cure for ovarian cancer has been given a boost by a $5 million gift that will support the clinical research of David S. Alberts, MD, an ... Read more